Loading...
XASXCGS
Market cap110mUSD
Dec 27, Last price  
1.04AUD
1D
0.00%
1Q
-1.89%
Jan 2017
-14.32%
Name

CogState Ltd

Chart & Performance

D1W1MN
XASX:CGS chart
P/E
20.34
P/S
1.67
EPS
0.03
Div Yield, %
0.00%
Shrs. gr., 5y
7.75%
Rev. gr., 5y
16.77%
Revenues
66m
+10.20%
782,1461,540,4481,993,0923,619,8346,770,9398,060,9848,692,53512,295,48511,373,51411,547,84812,328,28327,252,05535,012,76537,371,44430,531,04933,967,94843,818,79862,025,51660,137,14766,272,813
Net income
5m
+2.75%
00001,153,7861,391,76002,509,3250002,641,919-853,062-730,367-3,489,836-2,918,6497,015,64510,369,3125,304,0135,449,884
CFO
9m
+392.64%
-2,007,018-1,584,536-1,353,744-704,537914,5751,408,847510,1881,290,976-1,627,592-3,409,015-2,776,9252,630,5783,242,491-101,937608,3621,111,59021,605,92813,454,9941,760,4368,672,576
Earnings
Feb 20, 2025

Profile

Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
URL
https://cogstate.com/
IPO date
Feb 13, 2004
Employees
172
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
66,273
10.20%
60,137
-3.04%
62,026
41.55%
Cost of revenue
44,268
73,001
60,843
Unusual Expense (Income)
NOPBT
22,005
(12,863)
1,182
NOPBT Margin
33.20%
1.91%
Operating Taxes
2,476
(807)
4,375
Tax Rate
11.25%
370.08%
NOPAT
19,528
(12,057)
(3,193)
Net income
5,450
2.75%
5,304
-48.85%
10,369
47.80%
Dividends
Dividend yield
Proceeds from repurchase of equity
(2,967)
(296)
1,942
BB yield
1.53%
0.10%
-0.72%
Debt
Debt current
218
352
1,192
Long-term debt
1,018
67
1,454
Deferred revenue
5,194
5,246
8,800
Other long-term liabilities
458
43
303
Net debt
(43,870)
(42,660)
(41,850)
Cash flow
Cash from operating activities
8,673
1,760
13,455
CAPEX
(676)
(3,286)
(4,911)
Cash from investing activities
(1,675)
(3,286)
(4,911)
Cash from financing activities
(4,912)
(1,330)
1,048
FCF
17,348
(10,018)
(2,405)
Balance
Cash
45,106
43,080
44,495
Long term investments
Excess cash
41,793
40,073
41,394
Stockholders' equity
40,922
56,619
47,876
Invested Capital
26,677
25,809
15,971
ROIC
74.41%
ROCE
56.11%
2.03%
EV
Common stock shares outstanding
173,100
176,345
176,824
Price
1.12
-32.12%
1.65
8.20%
1.53
12.13%
Market cap
193,872
-33.37%
290,969
7.90%
269,657
14.57%
EV
150,002
248,308
227,807
EBITDA
22,005
(9,006)
4,387
EV/EBITDA
6.82
51.93
Interest
51
104
122
Interest/NOPBT
0.23%
10.30%